ProKidney Corp. Total Assets
ProKidney Corp. total assets. Based on the latest financial reports, ProKidney Corp. (PROK) holds total assets worth $249.02 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market value of ProKidney Corp. for the company's overall valuation and market capitalisation.
Total Assets of ProKidney Corp. (2019–2025)
Total assets of ProKidney Corp. from 2019 to 2025. This chart illustrates how ProKidney Corp.'s total assets have evolved over time, based on quarterly financial data. See ProKidney Corp. stock price for real-time trading data and today's change.
ProKidney Corp. - Asset Composition Analysis
ProKidney Corp. Total Assets Breakdown (December 2025)
ProKidney Corp. total assets breakdown as of December 2025. ProKidney Corp.'s total assets of $249.02 Million consist of 83.6% current assets and 16.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.3% |
| Accounts Receivable | $1.13 Million | 0.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how ProKidney Corp.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore PROK net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ProKidney Corp.'s current assets represent 83.6% of total assets in 2025, an increase from 78.7% in 2019.
- Cash Position: Cash and equivalents constituted 32.3% of total assets in 2025, down from 77.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
ProKidney Corp. Competitors by Total Assets
Key competitors of ProKidney Corp. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩12.65 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
|
China | CN¥20.70 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
USA | $852.49 Million |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
USA | $949.87 Million |
ProKidney Corp. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 8.36 | 11.48 | 0.82 |
| Quick Ratio | 8.36 | 11.48 | 0.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $167.06 Million | $296.18 Million | $-1.48 Million |
ProKidney Corp. - Advanced Valuation Insights
This section examines the relationship between ProKidney Corp.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 97.15 |
| Latest Market Cap to Assets Ratio | 0.71 |
| Asset Growth Rate (YoY) | -23.9% |
| Total Assets | $335.57 Million |
| Market Capitalization | $238.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values ProKidney Corp.'s assets below their book value (0.71x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: ProKidney Corp.'s assets decreased by 23.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for ProKidney Corp. (2019–2025)
The table below shows the annual total assets of ProKidney Corp. from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $335.57 Million | -23.92% |
| 2024-12-31 | $441.07 Million | +4.88% |
| 2023-12-31 | $420.55 Million | -18.81% |
| 2022-12-31 | $518.00 Million | +1185.41% |
| 2021-12-31 | $40.30 Million | +141.31% |
| 2020-12-31 | $16.70 Million | -14.83% |
| 2019-12-31 | $19.61 Million | -- |
About ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the devel… Read more